APO Research
Talk to an analyst

APO RESEARCH · REPORT

Candidiasis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Candidiasis Therapeutics Industry Growth and Trends Forecast to 2032

22 December 2025101 pages

Choose your research edition.

Industry ResearchCandidiasis Therapeutics Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Candidiasis Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Candidiasis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Candidiasis Therapeutics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Candidiasis Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Candidiasis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Candidiasis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Candidiasis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Candidiasis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Candidiasis Therapeutics include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer-Algeta, Amgen, Merrion Pharmaceuticals Plc., Medivir AB, Genta Incorporated, Galapagos NV and Digna Biotech S.L., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Candidiasis Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Candidiasis Therapeutics market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Candidiasis Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Candidiasis Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Candidiasis Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Candidiasis Therapeutics Market by Company

Novartis AG

F. Hoffmann-La Roche Ltd.

Bayer-Algeta

Amgen

Merrion Pharmaceuticals Plc.

Medivir AB

Genta Incorporated

Galapagos NV

Digna Biotech S.L.

Catena Pharmaceuticals Inc.

Amura Holdings

Ablynx

Candidiasis Therapeutics Segment by Type

Vincristine

Ifosfamide

Etoposide

Cisplatin

Methotrexate

Cyclophosphamide

Doxorubicin

7Carboplatin

Candidiasis Therapeutics Segment by Application

Multispecialty Hospitals

Cancer Research Institutes

Others

Candidiasis Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Candidiasis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Candidiasis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Candidiasis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Candidiasis Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Candidiasis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Vincristine Table 2. Major Company of Ifosfamide Table 3. Major Company of Etoposide Table 4. Major Company of Cisplatin Table 5. Major Company of Methotrexate Table 6. Major Company of Cyclophosphamide Table 7. Major Company of Doxorubicin Table 8. Major Company of 7Carboplatin Table 9. Global Candidiasis Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 10. Global Candidiasis Therapeutics Sales by Type (2021-2026) & (k units) Table 11. Global Candidiasis Therapeutics Sales Market Share in Volume by Type (2021-2026) Table 12. Global Candidiasis Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 13. Global Candidiasis Therapeutics Sales Market Share in Value by Type (2021-2026) Table 14. Global Candidiasis Therapeutics Price by Type (2021-2026) & (US$/unit) Table 15. Global Candidiasis Therapeutics Sales by Type (2027-2032) & (k units) Table 16. Global Candidiasis Therapeutics Sales Market Share in Volume by Type (2027-2032) Table 17. Global Candidiasis Therapeutics Sales by Type (2027-2032) & (US$ Million) Table 18. Global Candidiasis Therapeutics Sales Market Share in Value by Type (2027-2032) Table 19. Global Candidiasis Therapeutics Price by Type (2027-2032) & (US$/unit) Table 20. North America Candidiasis Therapeutics Sales by Type (2021-2026) & (k units) Table 21. North America Candidiasis Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 22. Europe Candidiasis Therapeutics Sales by Type (2021-2026) & (k units) Table 23. Europe Candidiasis Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 24. Asia-Pacific Candidiasis Therapeutics Sales by Type (2021-2026) & (k units) Table 25. Asia-Pacific Candidiasis Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 26. Latin America Candidiasis Therapeutics Sales by Type (2021-2026) & (k units) Table 27. Latin America Candidiasis Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 28. Middle East and Africa Candidiasis Therapeutics Sales by Type (2021-2026) & (k units) Table 29. Middle East and Africa Candidiasis Therapeutics Sales by Type (2021-2026) & (US$ Million) Table 30. Candidiasis Therapeutics Industry Trends Table 31. Candidiasis Therapeutics Industry Drivers Table 32. Candidiasis Therapeutics Industry Opportunities and Challenges Table 33. Candidiasis Therapeutics Industry Restraints Table 34. Global Candidiasis Therapeutics Sales Revenue by Company (US$ Million) & (2021-2026) Table 35. Global Candidiasis Therapeutics Revenue Market Share by Company (2021-2026) Table 36. Global Candidiasis Therapeutics Sales by Company (2021-2026) & (k units) Table 37. Global Candidiasis Therapeutics Sales Share by Company (2021-2026) Table 38. Global Candidiasis Therapeutics Market Price by Company (2021-2026) & (US$/unit) Table 39. Global Candidiasis Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 40. Global Candidiasis Therapeutics Major Company Production Sites and Headquarters Table 41. Global Candidiasis Therapeutics Company, Product Type & Application Table 42. Global Candidiasis Therapeutics Company Establishment Date Table 43. Global Company Market Concentration Ratio (CR5 and HHI) Table 44. Global Candidiasis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global Candidiasis Therapeutics Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 46. Global Candidiasis Therapeutics Sales by Region (2021-2026) & (k units) Table 47. Global Candidiasis Therapeutics Sales Market Share in Volume by Region (2021-2026) Table 48. Global Candidiasis Therapeutics Sales by Region (2021-2026) & (US$ Million) Table 49. Global Candidiasis Therapeutics Sales Market Share in Value by Region (2021-2026) Table 50. Global Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Global Candidiasis Therapeutics Sales by Region (2027-2032) & (k units) Table 52. Global Candidiasis Therapeutics Sales Market Share in Volume by Region (2027-2032) Table 53. Global Candidiasis Therapeutics Sales by Region (2027-2032) & (US$ Million) Table 54. Global Candidiasis Therapeutics Sales Market Share in Value by Region (2027-2032) Table 55. Global Candidiasis Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 56. Global Candidiasis Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Global Candidiasis Therapeutics Sales by Application (2021-2026) & (k units) Table 58. Global Candidiasis Therapeutics Sales Market Share in Volume by Application (2021-2026) Table 59. Global Candidiasis Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 60. Global Candidiasis Therapeutics Sales Market Share in Value by Application (2021-2026) Table 61. Global Candidiasis Therapeutics Price by Application (2021-2026) & (US$/unit) Table 62. Global Candidiasis Therapeutics Sales by Application (2027-2032) & (k units) Table 63. Global Candidiasis Therapeutics Sales Market Share in Volume by Application (2027-2032) Table 64. Global Candidiasis Therapeutics Sales by Application (2027-2032) & (US$ Million) Table 65. Global Candidiasis Therapeutics Sales Market Share in Value by Application (2027-2032) Table 66. Global Candidiasis Therapeutics Price by Application (2027-2032) & (US$/unit) Table 67. North America Candidiasis Therapeutics Sales by Application (2021-2026) & (k units) Table 68. North America Candidiasis Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 69. Europe Candidiasis Therapeutics Sales by Application (2021-2026) & (k units) Table 70. Europe Candidiasis Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 71. Asia-Pacific Candidiasis Therapeutics Sales by Application (2021-2026) & (k units) Table 72. Asia-Pacific Candidiasis Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 73. Latin America Candidiasis Therapeutics Sales by Application (2021-2026) & (k units) Table 74. Latin America Candidiasis Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 75. Middle East and Africa Candidiasis Therapeutics Sales by Application (2021-2026) & (k units) Table 76. Middle East and Africa Candidiasis Therapeutics Sales by Application (2021-2026) & (US$ Million) Table 77. Novartis AG Company Information Table 78. Novartis AG Business Overview Table 79. Novartis AG Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Novartis AG Candidiasis Therapeutics Product Portfolio Table 81. Novartis AG Recent Development Table 82. F. Hoffmann-La Roche Ltd. Company Information Table 83. F. Hoffmann-La Roche Ltd. Business Overview Table 84. F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Product Portfolio Table 86. F. Hoffmann-La Roche Ltd. Recent Development Table 87. Bayer-Algeta Company Information Table 88. Bayer-Algeta Business Overview Table 89. Bayer-Algeta Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Bayer-Algeta Candidiasis Therapeutics Product Portfolio Table 91. Bayer-Algeta Recent Development Table 92. Amgen Company Information Table 93. Amgen Business Overview Table 94. Amgen Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Amgen Candidiasis Therapeutics Product Portfolio Table 96. Amgen Recent Development Table 97. Merrion Pharmaceuticals Plc. Company Information Table 98. Merrion Pharmaceuticals Plc. Business Overview Table 99. Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Product Portfolio Table 101. Merrion Pharmaceuticals Plc. Recent Development Table 102. Medivir AB Company Information Table 103. Medivir AB Business Overview Table 104. Medivir AB Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Medivir AB Candidiasis Therapeutics Product Portfolio Table 106. Medivir AB Recent Development Table 107. Genta Incorporated Company Information Table 108. Genta Incorporated Business Overview Table 109. Genta Incorporated Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Genta Incorporated Candidiasis Therapeutics Product Portfolio Table 111. Genta Incorporated Recent Development Table 112. Galapagos NV Company Information Table 113. Galapagos NV Business Overview Table 114. Galapagos NV Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Galapagos NV Candidiasis Therapeutics Product Portfolio Table 116. Galapagos NV Recent Development Table 117. Digna Biotech S.L. Company Information Table 118. Digna Biotech S.L. Business Overview Table 119. Digna Biotech S.L. Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Digna Biotech S.L. Candidiasis Therapeutics Product Portfolio Table 121. Digna Biotech S.L. Recent Development Table 122. Catena Pharmaceuticals Inc. Company Information Table 123. Catena Pharmaceuticals Inc. Business Overview Table 124. Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Catena Pharmaceuticals Inc. Candidiasis Therapeutics Product Portfolio Table 126. Catena Pharmaceuticals Inc. Recent Development Table 127. Amura Holdings Company Information Table 128. Amura Holdings Business Overview Table 129. Amura Holdings Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Amura Holdings Candidiasis Therapeutics Product Portfolio Table 131. Amura Holdings Recent Development Table 132. Ablynx Company Information Table 133. Ablynx Business Overview Table 134. Ablynx Candidiasis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Ablynx Candidiasis Therapeutics Product Portfolio Table 136. Ablynx Recent Development Table 137. North America Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 138. North America Candidiasis Therapeutics Sales by Country (2021-2026) & (k units) Table 139. North America Candidiasis Therapeutics Sales Market Share by Country (2021-2026) Table 140. North America Candidiasis Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 141. North America Candidiasis Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 142. North America Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. North America Candidiasis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 144. North America Candidiasis Therapeutics Market Share by Country (2021-2026) Table 145. North America Candidiasis Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. North America Candidiasis Therapeutics Market Share Forecast by Country (2027-2032) Table 147. Europe Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 148. Europe Candidiasis Therapeutics Sales by Country (2021-2026) & (k units) Table 149. Europe Candidiasis Therapeutics Sales Market Share by Country (2021-2026) Table 150. Europe Candidiasis Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 151. Europe Candidiasis Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 152. Europe Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Europe Candidiasis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 154. Europe Candidiasis Therapeutics Market Share by Country (2021-2026) Table 155. Europe Candidiasis Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Europe Candidiasis Therapeutics Market Share Forecast by Country (2027-2032) Table 157. Asia-Pacific Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 158. Asia-Pacific Candidiasis Therapeutics Sales by Country (2021-2026) & (k units) Table 159. Asia-Pacific Candidiasis Therapeutics Sales Market Share by Country (2021-2026) Table 160. Asia-Pacific Candidiasis Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 161. Asia-Pacific Candidiasis Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 162. Asia-Pacific Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Asia-Pacific Candidiasis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 164. Asia-Pacific Candidiasis Therapeutics Market Share by Country (2021-2026) Table 165. Asia-Pacific Candidiasis Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Asia-Pacific Candidiasis Therapeutics Market Share Forecast by Country (2027-2032) Table 167. Latin America Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 168. Latin America Candidiasis Therapeutics Sales by Country (2021-2026) & (k units) Table 169. Latin America Candidiasis Therapeutics Sales Market Share by Country (2021-2026) Table 170. Latin America Candidiasis Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 171. Latin America Candidiasis Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 172. Latin America Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Latin America Candidiasis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 174. Latin America Candidiasis Therapeutics Market Share by Country (2021-2026) Table 175. Latin America Candidiasis Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Latin America Candidiasis Therapeutics Market Share Forecast by Country (2027-2032) Table 177. Middle East and Africa Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 178. Middle East and Africa Candidiasis Therapeutics Sales by Country (2021-2026) & (k units) Table 179. Middle East and Africa Candidiasis Therapeutics Sales Market Share by Country (2021-2026) Table 180. Middle East and Africa Candidiasis Therapeutics Sales Forecast by Country (2027-2032) & (k units) Table 181. Middle East and Africa Candidiasis Therapeutics Sales Market Share Forecast by Country (2027-2032) Table 182. Middle East and Africa Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Middle East and Africa Candidiasis Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 184. Middle East and Africa Candidiasis Therapeutics Market Share by Country (2021-2026) Table 185. Middle East and Africa Candidiasis Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Middle East and Africa Candidiasis Therapeutics Market Share Forecast by Country (2027-2032) Table 187. Key Raw Materials Table 188. Raw Materials Key Suppliers Table 189. Candidiasis Therapeutics Distributors List Table 190. Candidiasis Therapeutics Customers List Table 191. Research Programs/Design for This Report Table 192. Authors List of This Report Table 193. Secondary Sources Table 194. Primary Sources List of Figures Figure 1. Candidiasis Therapeutics Image Figure 2. Global Candidiasis Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Candidiasis Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Candidiasis Therapeutics Sales (2021-2032) & (k units) Figure 5. Vincristine Image Figure 6. Global Vincristine Sales YoY Growth (2021-2032) & (k units) Figure 7. Ifosfamide Image Figure 8. Global Ifosfamide Sales YoY Growth (2021-2032) & (k units) Figure 9. Etoposide Image Figure 10. Global Etoposide Sales YoY Growth (2021-2032) & (k units) Figure 11. Cisplatin Image Figure 12. Global Cisplatin Sales YoY Growth (2021-2032) & (k units) Figure 13. Methotrexate Image Figure 14. Global Methotrexate Sales YoY Growth (2021-2032) & (k units) Figure 15. Cyclophosphamide Image Figure 16. Global Cyclophosphamide Sales YoY Growth (2021-2032) & (k units) Figure 17. Doxorubicin Image Figure 18. Global Doxorubicin Sales YoY Growth (2021-2032) & (k units) Figure 19. 7Carboplatin Image Figure 20. Global 7Carboplatin Sales YoY Growth (2021-2032) & (k units) Figure 21. Global Candidiasis Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 22. Global Candidiasis Therapeutics Market Share by Type 2025 VS 2032 Figure 23. North America Candidiasis Therapeutics Sales Market Share in Volume by Type in 2025 Figure 24. North America Candidiasis Therapeutics Sales Market Share in Value by Type in 2025 Figure 25. Europe Candidiasis Therapeutics Sales Market Share in Volume by Type in 2025 Figure 26. Europe Candidiasis Therapeutics Sales Market Share in Value by Type in 2025 Figure 27. Asia-Pacific Candidiasis Therapeutics Sales Market Share in Volume by Type in 2025 Figure 28. Asia-Pacific Candidiasis Therapeutics Sales Market Share in Value by Type in 2025 Figure 29. Latin America Candidiasis Therapeutics Sales Market Share in Volume by Type in 2025 Figure 30. Latin America Candidiasis Therapeutics Sales Market Share in Value by Type in 2025 Figure 31. Middle East and Africa Candidiasis Therapeutics Sales Market Share in Volume by Type in 2025 Figure 32. Middle East and Africa Candidiasis Therapeutics Sales Market Share in Value by Type in 2025 Figure 33. Global Top 5 and 10 Candidiasis Therapeutics Players Market Share by Revenue in 2025 Figure 34. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 35. Multispecialty Hospitals Image Figure 36. Global Multispecialty Hospitals Sales YoY Growth (2021-2032) & (k units) Figure 37. Cancer Research Institutes Image Figure 38. Global Cancer Research Institutes Sales YoY Growth (2021-2032) & (k units) Figure 39. Others Image Figure 40. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 41. Global Candidiasis Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Candidiasis Therapeutics Market Share by Application 2025 VS 2032 Figure 43. North America Candidiasis Therapeutics Sales Market Share in Volume by Application in 2025 Figure 44. North America Candidiasis Therapeutics Sales Market Share in Value by Application in 2025 Figure 45. Europe Candidiasis Therapeutics Sales Market Share in Volume by Application in 2025 Figure 46. Europe Candidiasis Therapeutics Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific Candidiasis Therapeutics Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific Candidiasis Therapeutics Sales Market Share in Value by Application in 2025 Figure 49. Latin America Candidiasis Therapeutics Sales Market Share in Volume by Application in 2025 Figure 50. Latin America Candidiasis Therapeutics Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa Candidiasis Therapeutics Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa Candidiasis Therapeutics Sales Market Share in Value by Application in 2025 Figure 53. North America Candidiasis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. North America Candidiasis Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America Candidiasis Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Candidiasis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Europe Candidiasis Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe Candidiasis Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Candidiasis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Asia-Pacific Candidiasis Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific Candidiasis Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Candidiasis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Latin America Candidiasis Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America Candidiasis Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Candidiasis Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 70. Middle East and Africa Candidiasis Therapeutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa Candidiasis Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Candidiasis Therapeutics Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. Candidiasis Therapeutics Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Vincristine
  • Ifosfamide
  • Etoposide
  • Cisplatin
  • Methotrexate
  • Cyclophosphamide
  • Doxorubicin
  • 7Carboplatin
Applications
  • Multispecialty Hospitals
  • Cancer Research Institutes
  • Others
Companies covered
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Bayer-Algeta
  • Amgen
  • Merrion Pharmaceuticals Plc.
  • Medivir AB
  • Genta Incorporated
  • Galapagos NV
  • Digna Biotech S.L.
  • Catena Pharmaceuticals Inc.
  • Amura Holdings
  • Ablynx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Candidiasis Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Candidiasis Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Candidiasis Therapeutics Market by Type
  6. 1.3.1 Vincristine
  7. 1.3.2 Ifosfamide
  8. 1.3.3 Etoposide
  9. 1.3.4 Cisplatin
  10. 1.3.5 Methotrexate
  11. 1.3.6 Cyclophosphamide
  12. 1.3.7 Doxorubicin
  13. 1.3.8 7Carboplatin
  14. 1.4 Global Candidiasis Therapeutics Market Size by Type
  15. 1.4.1 Global Candidiasis Therapeutics Market Size Overview by Type (2021-2032)
  16. 1.4.2 Global Candidiasis Therapeutics Historic Market Size Review by Type (2021-2026)
  17. 1.4.3 Global Candidiasis Therapeutics Forecasted Market Size by Type (2027-2032)
  18. 1.5 Key Regions Market Size by Type
  19. 1.5.1 North America Candidiasis Therapeutics Sales Breakdown by Type (2021-2026)
  20. 1.5.2 Europe Candidiasis Therapeutics Sales Breakdown by Type (2021-2026)
  21. 1.5.3 Asia-Pacific Candidiasis Therapeutics Sales Breakdown by Type (2021-2026)
  22. 1.5.4 South America Candidiasis Therapeutics Sales Breakdown by Type (2021-2026)
  23. 1.5.5 Middle East and Africa Candidiasis Therapeutics Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Candidiasis Therapeutics Industry Trends
  2. 2.2 Candidiasis Therapeutics Industry Drivers
  3. 2.3 Candidiasis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Candidiasis Therapeutics Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Candidiasis Therapeutics Revenue (2021-2026)
  2. 3.2 Global Top Players by Candidiasis Therapeutics Sales (2021-2026)
  3. 3.3 Global Top Players by Candidiasis Therapeutics Price (2021-2026)
  4. 3.4 Global Candidiasis Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Candidiasis Therapeutics Major Company Production Sites & Headquarters
  6. 3.6 Global Candidiasis Therapeutics Company, Product Type & Application
  7. 3.7 Global Candidiasis Therapeutics Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Candidiasis Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Candidiasis Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Candidiasis Therapeutics Tier 1, Tier 2, and Tier 3
4 Candidiasis Therapeutics Regional Status and Outlook
  1. 4.1 Global Candidiasis Therapeutics Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Candidiasis Therapeutics Historic Market Size by Region
  3. 4.2.1 Global Candidiasis Therapeutics Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Candidiasis Therapeutics Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Candidiasis Therapeutics Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Candidiasis Therapeutics Forecasted Market Size by Region
  7. 4.3.1 Global Candidiasis Therapeutics Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Candidiasis Therapeutics Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Candidiasis Therapeutics Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Candidiasis Therapeutics by Application
  1. 5.1 Candidiasis Therapeutics Market by Application
  2. 5.1.1 Multispecialty Hospitals
  3. 5.1.2 Cancer Research Institutes
  4. 5.1.3 Others
  5. 5.2 Global Candidiasis Therapeutics Market Size by Application
  6. 5.2.1 Global Candidiasis Therapeutics Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Candidiasis Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Candidiasis Therapeutics Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Candidiasis Therapeutics Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Candidiasis Therapeutics Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Candidiasis Therapeutics Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Candidiasis Therapeutics Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Candidiasis Therapeutics Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG Candidiasis Therapeutics Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 F. Hoffmann-La Roche Ltd.
  8. 6.2.1 F. Hoffmann-La Roche Ltd. Company Information
  9. 6.2.2 F. Hoffmann-La Roche Ltd. Business Overview
  10. 6.2.3 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Product Portfolio
  12. 6.2.5 F. Hoffmann-La Roche Ltd. Recent Developments
  13. 6.3 Bayer-Algeta
  14. 6.3.1 Bayer-Algeta Company Information
  15. 6.3.2 Bayer-Algeta Business Overview
  16. 6.3.3 Bayer-Algeta Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bayer-Algeta Candidiasis Therapeutics Product Portfolio
  18. 6.3.5 Bayer-Algeta Recent Developments
  19. 6.4 Amgen
  20. 6.4.1 Amgen Company Information
  21. 6.4.2 Amgen Business Overview
  22. 6.4.3 Amgen Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Amgen Candidiasis Therapeutics Product Portfolio
  24. 6.4.5 Amgen Recent Developments
  25. 6.5 Merrion Pharmaceuticals Plc.
  26. 6.5.1 Merrion Pharmaceuticals Plc. Company Information
  27. 6.5.2 Merrion Pharmaceuticals Plc. Business Overview
  28. 6.5.3 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Product Portfolio
  30. 6.5.5 Merrion Pharmaceuticals Plc. Recent Developments
  31. 6.6 Medivir AB
  32. 6.6.1 Medivir AB Company Information
  33. 6.6.2 Medivir AB Business Overview
  34. 6.6.3 Medivir AB Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Medivir AB Candidiasis Therapeutics Product Portfolio
  36. 6.6.5 Medivir AB Recent Developments
  37. 6.7 Genta Incorporated
  38. 6.7.1 Genta Incorporated Company Information
  39. 6.7.2 Genta Incorporated Business Overview
  40. 6.7.3 Genta Incorporated Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Genta Incorporated Candidiasis Therapeutics Product Portfolio
  42. 6.7.5 Genta Incorporated Recent Developments
  43. 6.8 Galapagos NV
  44. 6.8.1 Galapagos NV Company Information
  45. 6.8.2 Galapagos NV Business Overview
  46. 6.8.3 Galapagos NV Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Galapagos NV Candidiasis Therapeutics Product Portfolio
  48. 6.8.5 Galapagos NV Recent Developments
  49. 6.9 Digna Biotech S.L.
  50. 6.9.1 Digna Biotech S.L. Company Information
  51. 6.9.2 Digna Biotech S.L. Business Overview
  52. 6.9.3 Digna Biotech S.L. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Digna Biotech S.L. Candidiasis Therapeutics Product Portfolio
  54. 6.9.5 Digna Biotech S.L. Recent Developments
  55. 6.10 Catena Pharmaceuticals Inc.
  56. 6.10.1 Catena Pharmaceuticals Inc. Company Information
  57. 6.10.2 Catena Pharmaceuticals Inc. Business Overview
  58. 6.10.3 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Product Portfolio
  60. 6.10.5 Catena Pharmaceuticals Inc. Recent Developments
  61. 6.11 Amura Holdings
  62. 6.11.1 Amura Holdings Company Information
  63. 6.11.2 Amura Holdings Business Overview
  64. 6.11.3 Amura Holdings Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Amura Holdings Candidiasis Therapeutics Product Portfolio
  66. 6.11.5 Amura Holdings Recent Developments
  67. 6.12 Ablynx
  68. 6.12.1 Ablynx Company Information
  69. 6.12.2 Ablynx Business Overview
  70. 6.12.3 Ablynx Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Ablynx Candidiasis Therapeutics Product Portfolio
  72. 6.12.5 Ablynx Recent Developments
7 North America by Country
  1. 7.1 North America Candidiasis Therapeutics Sales by Country
  2. 7.1.1 North America Candidiasis Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Candidiasis Therapeutics Sales by Country (2021-2026)
  4. 7.1.3 North America Candidiasis Therapeutics Sales Forecast by Country (2027-2032)
  5. 7.2 North America Candidiasis Therapeutics Market Size by Country
  6. 7.2.1 North America Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Candidiasis Therapeutics Market Size by Country (2021-2026)
  8. 7.2.3 North America Candidiasis Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Candidiasis Therapeutics Sales by Country
  2. 8.1.1 Europe Candidiasis Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Candidiasis Therapeutics Sales by Country (2021-2026)
  4. 8.1.3 Europe Candidiasis Therapeutics Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Candidiasis Therapeutics Market Size by Country
  6. 8.2.1 Europe Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Candidiasis Therapeutics Market Size by Country (2021-2026)
  8. 8.2.3 Europe Candidiasis Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Candidiasis Therapeutics Sales by Country
  2. 9.1.1 Asia-Pacific Candidiasis Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Candidiasis Therapeutics Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Candidiasis Therapeutics Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Candidiasis Therapeutics Market Size by Country
  6. 9.2.1 Asia-Pacific Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Candidiasis Therapeutics Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Candidiasis Therapeutics Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Candidiasis Therapeutics Sales by Country
  2. 10.1.1 South America Candidiasis Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Candidiasis Therapeutics Sales by Country (2021-2026)
  4. 10.1.3 South America Candidiasis Therapeutics Sales Forecast by Country (2027-2032)
  5. 10.2 South America Candidiasis Therapeutics Market Size by Country
  6. 10.2.1 South America Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Candidiasis Therapeutics Market Size by Country (2021-2026)
  8. 10.2.3 South America Candidiasis Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Candidiasis Therapeutics Sales by Country
  2. 11.1.1 Middle East and Africa Candidiasis Therapeutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Candidiasis Therapeutics Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Candidiasis Therapeutics Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Candidiasis Therapeutics Market Size by Country
  6. 11.2.1 Middle East and Africa Candidiasis Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Candidiasis Therapeutics Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Candidiasis Therapeutics Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Candidiasis Therapeutics Value Chain Analysis
  2. 12.1.1 Candidiasis Therapeutics Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Candidiasis Therapeutics Production Mode & Process
  7. 12.2 Candidiasis Therapeutics Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Candidiasis Therapeutics Distributors
  10. 12.2.3 Candidiasis Therapeutics Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst